<DOC>
	<DOC>NCT00858871</DOC>
	<brief_summary>The purpose of this study is to compare the overall survival of brivanib versus sorafenib in subjects with advanced HCC who have not received prior systemic therapy.</brief_summary>
	<brief_title>First Line Hepato Cellular Carcinoma (HCC)</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma, Hepatocellular</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<criteria>For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com. Histologic or cytologic confirmed diagnosis of HCC. Advanced HCC: disease not eligible for surgical and/or locoregional therapies OR progressive disease after surgical and/or locoregional therapies ChildPugh Class A ECOG performance status 01 Adequate hematologic, hepatic, and renal function Prior use of any systemic anticancer chemotherapy, immunotherapy or molecular targeted agents for HCC History of active cardiac disease Thrombotic or embolic events within the past 6 months (except HCC tumor thrombus) Any other hemorrhage/bleeding event &gt;= CTCAE Grade 3 within 8 weeks except for esophageal or gastric varices Inability to swallow tablets or untreated malabsorption syndrome</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>